Life Sciences

Mintz’s Life Sciences practice is a multidisciplinary team of more than 250 attorneys and professionals advising companies, investors, and institutions at the intersection of scientific innovation, intellectual property, capital formation, and regulatory strategy. The firm represents leading pharmaceutical and biotechnology companies, including Amgen, Eli Lilly, Sanofi, QIAGEN, and Fulgent Genetics, as well as prominent life sciences investors and financial institutions.

The practice is built on the premise that value in the life sciences sector is driven by the strategic alignment of intellectual property, capital planning, and regulatory execution across a company’s full lifecycle. Mintz advises clients from early development through commercialization, enforcement, and exit, providing integrated guidance as financing structures, collaboration models, and competitive pressures continue to evolve.